Dasatinib and Crizotinib in Advanced Cancer

Inclusion Criteria:

1. Patients must have histologically confirmed solid malignancy that is metastatic or unresectable or lymphoma, for which standard curative or palliative measures that improve survival by at least three months do not exist or are no longer effective. For the purpose of this study patients with leukemia are not eligible.
2. Age \>/= 16 years.
3. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.
4. Patients must have normal organ and marrow function as followed defined: ANC \>/= 1,000/mcL; Plt \>/=75,000/mcL; total bilirubin \</=2.0 mg/dL; AST (TGO)/ALT (TGP) \</=2.5x upper limit of normal; if liver metastasis are present, then \</= 5.0x upper limit; estimated creatinine clearance by Cockcroft-Gault equation \> 30 mL/min
5. The effects of Dasatinib and Crizotinib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
6. Patients receiving palliative radiation will be eligible after a wash-out period of 2 weeks between finishing radiation and initiation of study drugs. Palliative radiation will not be allowed during cycle 1 of treatment but is permitted in this study during following cycles as long as there are evaluable lesions that are not being irradiated
7. Signed informed consent approved by the Institutional Review Board prior to patient entry.
8. Expanded cohort only: Cohort 1: patients with predominant metastatic bone disease; Cohort 2: patients with primary squamous head and neck cancers; Cohort 3: patients presenting any molecular abnormality of interest, which can include an ALK translocation, ALK amplification, ALK mutation and overexpression as determined by FISH, IHC, qPCR, qRT-PCR, array Comparative Genomic Hybridization or direct sequencing (aCGH); a c-MET abnormality, either c-MET amplification by FISH, overexpression by IHC or c-MET mutation; BRAF, DDR2 and CDKN2A mutations; and, finally, TRIM 16 expression and CCN2 expression.

Exclusion Criteria:

1. Patient receiving any concurrent chemotherapy.
2. Concurrent severe and/or uncontrolled medical disease including, but not limited to, ongoing or active infection requiring intravenous antibiotics.
3. Symptomatic congestive heart failure (NYHA Class III or IV), or unstable angina pectoris.
4. Presence of symptomatic pleural and/or pericardial effusion not appropriated treated.
5. Prolonged QTc interval (\>/=500 msec), as calculated by Bazett's formula.
6. Psychiatric problems of sufficient severity to limit full compliance with the study or expose patients to undue risk.
7. Known anaphylactic or severe hypersensitivity to Dasatinib or Crizotinib or their analogs.
8. Patient has failed to recover from any prior surgery within 4 weeks of study entry.
9. Patient is pregnant or lactating. Pregnant women are excluded from this study because dasatinib and crizotinib are agents with the potential for teratogenic or abortifacient effects (Pregnancy category D).
10. Patient has had any treatment specific for tumor control within 3 weeks of dosing with investigational drugs and cytotoxic agents, or within 2 weeks of cytotoxic agent given weekly, or within 6 weeks of nitrosoureas or mitomycin C, or within 5 half-lives of biological targeted agents.
11. Patient is not able to swallow oral medication.
12. Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 complex are ineligible.
13. Patients with known pulmonary hypertension.